Evidence map›Paper›PMID 37002253›Full record

SynthesisScientific reports2023

Genetic correlations between Alzheimer's disease and gut microbiome genera.

Davis Cammann, Yimei Lu, Melika J Cummings, Mark L Zhang, Joan Manuel Cue, Jenifer Do, Jeffrey Ebersole, Xiangning Chen, Edwin C Oh, Jeffrey L Cummings and 1 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 1 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. The microbiota-proteostasis axis: implications in neurodegenerative diseases.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026
    Review
  5. Article
  6. Alterations of gut microbiota in Down syndrome and their association with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  7. Trehalose's untapped mechanisms in alzheimer's: gut-brain-autophagy signalling beyond the usual targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Davis Cammann *Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas 4505 S. Maryland Parkway, Las Vegas, NV, 89154, USA.
Yimei Lu *Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas 4505 S. Maryland Parkway, Las Vegas, NV, 89154, USA.
Melika J CummingsNevada Institute of Personalized Medicine, University of Nevada, Las Vegas 4505 S. Maryland Parkway, Las Vegas, NV, 89154, USA.
Mark L ZhangColumbia University, West 116 St and Broadway, New York, NY, 10027, USA.
Joan Manuel CueNevada Institute of Personalized Medicine, University of Nevada, Las Vegas 4505 S. Maryland Parkway, Las Vegas, NV, 89154, USA.
Jenifer DoNevada Institute of Personalized Medicine, University of Nevada, Las Vegas 4505 S. Maryland Parkway, Las Vegas, NV, 89154, USA.
Jeffrey EbersoleDepartment of Biomedical Sciences, University of Nevada, Las Vegas, NV, 89154, USA.
Xiangning ChenCenter for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Edwin C OhNevada Institute of Personalized Medicine, University of Nevada, Las Vegas 4505 S. Maryland Parkway, Las Vegas, NV, 89154, USA.
Jeffrey L CummingsDepartment of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.
Jingchun ChenNevada Institute of Personalized Medicine, University of Nevada, Las Vegas 4505 S. Maryland Parkway, Las Vegas, NV, 89154, USA. Jingchun.chen@unlv.edu.
University of Nevada, Las Vegas · USColumbia University · USThe University of Texas Health Science Center at Houston · US

Funding

Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI JESSICA KIRKLAND CALDWELL · 2015 to 2026
$22.8M
The Genome Analysis and Sequencing Pipeline (GASP)P20GM121325 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI CHEN, JINGCHUN · 2018 to 2022
$11.5M
Alzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9M
NIA NIH HHS R35 AG071476NIGMS NIH HHS P20 GM109025NIGMS NIH HHS P20 GM121325
6 · The paper itself

Abstract

A growing body of evidence suggests that dysbiosis of the human gut microbiota is associated with neurodegenerative diseases like Alzheimer's disease (AD) via neuroinflammatory processes across the microbiota-gut-brain axis. The gut microbiota affects brain health through the secretion of toxins and short-chain fatty acids, which modulates gut permeability and numerous immune functions. Observational studies indicate that AD patients have reduced microbiome diversity, which could contribute to the pathogenesis of the disease. Uncovering the genetic basis of microbial abundance and its effect on AD could suggest lifestyle changes that may reduce an individual's risk for the disease. Using the largest genome-wide association study of gut microbiota genera from the MiBioGen consortium, we used polygenic risk score (PRS) analyses with the "best-fit" model implemented in PRSice-2 and determined the genetic correlation between 119 genera and AD in a discovery sample (ADc12 case/control: 1278/1293). To confirm the results from the discovery sample, we next repeated the PRS analysis in a replication sample (GenADA case/control: 799/778) and then performed a meta-analysis with the PRS results from both samples. Finally, we conducted a linear regression analysis to assess the correlation between the PRSs for the significant genera and the APOE genotypes. In the discovery sample, 20 gut microbiota genera were initially identified as genetically associated with AD case/control status. Of these 20, three genera (Eubacterium fissicatena as a protective factor, Collinsella, and Veillonella as a risk factor) were independently significant in the replication sample. Meta-analysis with discovery and replication samples confirmed that ten genera had a significant correlation with AD, four of which were significantly associated with the APOE rs429358 risk allele in a direction consistent with their protective/risk designation in AD association. Notably, the proinflammatory genus Collinsella, identified as a risk factor for AD, was positively correlated with the APOE rs429358 risk allele in both samples. Overall, the host genetic factors influencing the abundance of ten genera are significantly associated with AD, suggesting that these genera may serve as biomarkers and targets for AD treatment and intervention. Our results highlight that proinflammatory gut microbiota might promote AD development through interaction with APOE. Larger datasets and functional studies are required to understand their causal relationships.

Indexed as

Alzheimer DiseaseGastrointestinal MicrobiomeMicrobiotaApolipoproteins EGenome-Wide Association StudyHumansApolipoproteins E

Identifiers

PMID37002253
PMCPMC10066300
OpenAlexW4362471972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.